Biotech Co.* |
Pharma Co. |
Type/Product Area | Terms/Details (Date) |
Abeille |
SymBio |
SymBio got rights to develop and sell AB-1001 in Japan, China, Korea, Taiwan and Singapore; AB-1001 is a transdermal patch for chemotherapy-induced nausea and vomiting |
Abeille gets an up-front licensing fee and potential milestone payments of up to $21M; it also would get double-digit royalties; SymBio also got a right of first refusal on Abeille's next product in the field (3/15) |
Abraxis |
Pfizer Inc. |
Acquisition of Pfizer's Puerto Rican manufacturing facility |
The 56-acre site consists of a validated manufacturing plant for injectable pharmaceuticals, protein-based biologics and metered-dosed inhalers; Abraxis will lease the plant back to Pfizer (2/15) |
Adnexus |
Bristol-Myers Squibb Co. |
Collaboration worldwide to discover compounds designed to modulate oncology targets using Adnexus' PROfusion technology |
Adnexus could deliver up to six preclinical candidates to BMS, which will take over development and commercialization, in exchange for development milestone payments of up to $210M for each compound (2/26) |
Anacor |
Schering-Plough Corp. |
Agreement for Schering- Plough to develop ANA2690 for onychomycosis and other indications |
Anacor retains an option to co-promote in the U.S. as part of the worldwide deal; it is receiving a $40M up-front payment, a $10M financing and up to $575M in potential milestone payments, along with royalties (2/2) |
Avalon |
Merck & Co. Inc. |
Partnership to discover and develop compounds against an intractable target believed to be important in the development of cancer |
Avalon could receive more than $200M in milestone payments from the deal, as well as royalties on any resulting sales (3/7) |
BD Biosciences |
Roche Bioscience (unit of F. Hoffmann- La Roche Ltd.; Switzerland) |
Collaboration to identify and develop intracellular phosphorylation site antibodies aimed at improving their understanding of the pathways that carry information inside of cells and why those pathways sometimes malfunction to cause disease |
The companies also will develop and validate antibodies for those targets using BD PhosFlow technology and in other cell and tissue analysis applications (2/26) |
BioAlliance |
Spepharm BV (the Netherlands) |
They entered a 50-50 joint venture for the marketing of Loramyc in Europe; it was approved in France in October for oropharyngeal candidiasis |
Spepharm is making a €5M equity investment in BioAlliance, and paying another €24.5M in license fees, €21.5M of which is tied to approvals in two countries and sales performance (3/14)** |
BioCryst |
Shionogi & Co. Ltd. (Japan) |
Licensing agreement for Japanese rights to the influenza antiviral peramivir |
Shionogi gains Japanese rights in return for a $14M up-front payment and potential clinical milestones of up to $21M and sales milestones of up to $95M; upon commercialization in Japan, BioCryst would be eligible for royalty payments in the range of 10% to 20% (3/6) |
BioLineRx Ltd.* |
Yeda Research and Development Co. Ltd. (Israel) |
Agreement under which BioLineRx in- licensed BL-3040, a small molecule for estrogen-related malignancies and osteoporosis; and BL-3050, a protein complex for treating atherosclerosis |
Terms of the deal were not disclosed (3/26) |
BrainCells Inc.* |
H. Lundbeck A/S (Denmark) |
Research collaboration in which BCI will use its neurogenesis-based technology to screen central nervous system targets and compounds to determine whether they promote neurogenesis |
Lundbeck plans to advance any targets or compounds identified through development for CNS indications (3/27) |
Cell Signaling |
Merck & Co. Inc. |
Collaboration to provide Merck with CST's PhosphoScan proteomics technology for biomarker discovery, and its expertise in antibody development and validation |
The goal is to develop high-specificity biomarker assays to help advance Merck's targeted therapeutic programs for oncology (3/28) |
ChemDiv Inc.* |
Kaken Pharmaceutical Co. (Japan) |
Joint drug discovery collaboration involving undisclosed therapeutic targets |
ChemDiv will produce lead candidates using its Discovery outSource platform; the chemical libraries will be screened for Kaken's drug targets (2/26) |
Clinquest Group* |
TNO Pharma (the Netherlands) |
License and collaboration agreement for exclusive rights to worldwide clinical development and commercialization of CQ- 7001 for anti-inflammatory and tissue regeneration applications |
TNO gets milestone fees and royalty payments (3/6) |
Cubist |
Merck & Co. Inc. |
License agreement for the development and commercialization of the antibiotic Cubicin worldwide |
Merck will make an up-front cash payment of $6M to Cubist, plus up to $39.5M in regulatory and sales milestones; it also agreed to make a transfer payment to include the cost of producing Cubicin and an amount payable to Eli Lilly & Co., which originally developed the product (3/22) |
Dyax Corp. |
Glenmark Pharmaceuticals SA (Switzerland; subsidiary of Glenmark Pharmaceuticals Ltd.; India) |
Research agreement for the discovery of therapeutic antibodies |
Dyax will work to identify antibodies for three targets provided by Glenmark; Dyax will receive technology license fees and full-time employee payments from Glenmark, as well as potential milestone and royalty payments (3/12) |
elbion* (Belgium) |
Wyeth |
Agreement focuses on schizophrenia; includes up-front fee, research funding and milestone payments as the PDE10 program moves forward |
Centered on elbion's program exploring inhibitors of phosphodiesterase 10, which degrades cAMP and cGMP, molecules responsible for improving the function of several cells in the body, including neurons (2/5) |
Evotec AG |
Boehringer Ingelheim GmbH (Germany) |
Deal to jointly identify novel targets as points of intervention in the treatment of Alzheimer's disease |
Evotec will work with the Research Institute of Molecular Pathology in Vienna to identify targets; BI will select candidates for its in-house drug discovery program; Evotec has an option to support BI in the target-validation process, which would entitle it to up to €20M in milestone payments, plus royalties (3/19) |
Favrille Inc. |
Berlex Inc. (affiliate of Bayer Schering Pharma AG; Germany) |
Agreement to study the use of Favrille's active immuno-therapy, FavId, in conjunction with Berlex's growth factor in patients with B-cell non-Hodgkin's lymphoma |
Terms were not disclosed (2/14) |
GW |
Otsuka Pharmaceutical Co. Ltd. (Japan) |
Agreement for development and U.S. marketing rights to GW's cannabinoid cancer pain compound, Sativex |
The deal is worth $18M up front to GW, and potentially worth another $255M in milestone payments; GW also is entitled to supply and royalty payments (2/14) |
Integrated |
Genencor International Inc. (unit of Danisco A/S; Denmark) |
Licensing agreement for Integrated's ERGO bio-informatics software system |
The software platform integrates biological data from genomics, biochemistry, gene expression studies, genetics and literature; financial terms were not disclosed (2/21) |
KeyNeurotek |
Grunenthal GmbH (Germany) |
Exclusive licensing agreement to take over development and marketing rights to GRT 203 |
The compound, in development for treating aconuresis via the central nervous system, has completed Phase I trials (3/1) |
KineMed Inc.* |
Bayer HealthCare AG (Germany) |
Collaboration to use KineMed's translational medicine technologies to discover new applications of existing compounds |
KineMed has co-development options on resulting therapeutics (2/6) |
KineMed Inc.* |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Collaboration to jointly validate its translational KineMarker technology |
The technology measures the on-mechanism activity of compounds in whole body systems in animals and humans (3/1) |
Medivir AB |
Guangdong Lantai Viewland Pharma- ceutical Co. Ltd. (China) |
Licensing agreement for a non-nucleoside HIV reverse transcriptase inhibitor, MIV-160, which is in late preclinical development |
Guangdong Lantai will transfer equity to Medivir, as well as pay royalties on sales for oral and topical use of the drug in China, including Hong Kong, Taiwan and Macao; Medivir retains rights in all other territories (2/12) |
MGI Pharma |
Helsinn Healthcare SA (Switzerland) |
Five-year U.S. patent extension agreement for Aloxi (palonosetron hydrochloride) injection |
Aloxi is approved for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderate and highly emetogenic cancer chemotherapy (2/13) |
Molecular |
Roche (Switzerland) |
Collaboration for designed repeat protein technology for a variety of undisclosed applications |
Molecular will select DARPins to a variety of targets provided by Roche, and Roche will do analyses and development (2/28) |
Nautilus |
HanAll Pharmaceutical Co. Ltd. (Korea) |
Collaboration and license agreement to develop and commercialize three Nautilus products in South Korea: Belerofon, Vitatropin and Eporal |
Nautilus will continue to pursue the clinical development of the products in the U.S.; terms include an up-front payment for Nautilus and potential milestones and royalties (3/6) |
Nautilus Biotech* (France) |
Wyeth |
Collaboration to find longer-acting Factor IX proteins for hemophilia B |
Nautilus will apply its protein engineering; the deal brings cash up front, plus research and development funding, milestone payments and royalties (2/5) |
Novelix |
AOP Orphan Pharmaceuticals AG (Austria) |
Exclusive licensing agreement for NVX-207 |
AOP can develop and commercialize the compound in human orphan designations in all territories outside the U.S. (2/26) |
Oxford |
Sanofi-Aventis SA (France) |
Licensing agreement for the cancer drug Trovax, which is in Phase III trials |
The $690M deal includes a $38.6M up- front payment; remaining funds will come from milestone achievements in various indications; Oxford BioMedica also is entitled to escalating royalties and to commercial milestones (3/28) |
Penwest |
Pharmaceutical International Inc. |
Collaboration agreement under which PII will conduct formulation work for Penwest and third parties for drugs using Penwest's oral drug delivery technologies, TIMERx, Geminex and Syncrodose |
PII will assume responsibility for formulation development and technical guidance and oversight from Penwest, and may assume responsibility for clinical trial material manufacturing and commercial manufacturing (3/28) |
Pharmacopeia |
NV Organon (the Netherlands) |
Collaboration to discover and develop small-molecule drugs against a range of indications |
Pharmacopeia will receive a $15M up-front payment, plus $4M in research funding for each year of the five-year agreement (2/13) |
Procognia Ltd.* |
GlaxoSmithKline plc (UK) |
Collaboration to explore the use of Procogonia's arrays within the GSK drug development processes |
The deal will combine Procognia's functional protein array technology and GSK's fluorescently labeled broad-specificity kinase inhibitors (3/23) |
ProMetic |
Kedrion SpA (Italy) |
Deal to develop orphan drugs derived from human plasma using ProMetic's manufacturing process |
Specific terms were not disclosed, but they would share in revenue derived from resulting sales; they initially will target Europe (3/13) |
ProNAi |
Novasom AG (Germany) |
Collaboration to enable delivery of DNAi- based cancer therapeutics |
ProNAi will license Novosom's Smarticles liposome technology for use in all diseases targeted by its PNT100 drug candidate in exchange for up-front, milestone and royalty payments; ProNAi also retains an option to four additional DNAi targets (3/6) |
Regeneron |
AstraZeneca plc (UK) |
Licensing deal for an antibody discovery technology |
AstraZeneca paid Regeneron a $20M license fee, as well as $20M per year over the next five years, for a potential of $120M; Regeneron also would get a mid-single- digit royalty on any resulting sales; Astra-Zeneca is free to generate human antibodies in any area of interest (2/5) |
Salix |
Merck & Co. Inc. |
Salix purchased U.S. rights to Pepcid oral suspension and Diuril oral suspension |
Salix paid $55M up front and Merck is entitled to up to $6M in potential sales-based milestone payments; Salix also entered a credit facility with Bank of America NA for up to $100M to help finance the transaction (2/28) |
Samaritan |
Pharmaplaz Ltd. (Ireland) |
Partnership for the development and commercialization of the Phase II HIV drug SP-01A |
Samaritan will get a $10M cash infusion as part of the deal, including $1.4M in an up-front payment and $8.6M due Sept. 16; Pharmaplaz will assume clinical development and manufacturing (3/28) |
Stem Cell |
Merck & Co. Inc. |
Licensing deal for use of Stem Cell's mouse neural stem cell technology for use in research |
SCS is entitled to a signing fee and potential milestone payments; further terms were not disclosed (2/20) |
Topigen |
Novagali Pharma SA (France) |
Agreement to swap technologies through a strategic collaboration |
Topigen will provide access to its RNA targeting platform while Novagali will provide a license to its topical drug delivery formulation (3/22) |
TopoTarget |
Novartis AG (Switzerland) |
TopoTarget exercised its option to gain rights to the cancer antibody Zenmab |
Rights to the ERBB2/Her2-targeting agent came from an option agreement signed in 2003; terms of the deal were not disclosed (3/12) |
TransTech |
Novo Nordisk A/S (Denmark) |
Agreement under which TransTech reacquired all rights to a glucokinase activator program that it had partnered with Novo more than five years ago |
Transtech acquired small-molecule, clinical and preclinical compounds, as well as intellectual property through an exclusive license with Novo, which said it is shifting its focus to protein-based drugs; Novo is entitled to an up-front fee and milestone and royalty payments (2/21) |
Vaccinex Inc.* |
Teva Pharmaceuticals Inc. (Israel) |
Agreement to develop and sell Vaccinex's preclinical antibody VX15 for multiple sclerosis |
Teva has an option to co-develop the drug for oncology indications as well; the deal is linked to a $25M financing in which Teva will participate (2/27) |
VASTox plc (UK; |
Rotapharm SpA (Italy); and an unnamed European biotech firm |
Long-term genomics dealswith a combined valueof $1M |
The first deal with Rotapharm involves the generation of a screening model for osteoarthritis; the second deal will involve VASTox's medicinal chemistry expertise in a research collaboration to support the client's drug discovery programs (2/13) |
Vivalis* (France) |
Sanofi Pasteur SA (France) |
Agreement for Vivalis' chicken and duck embry- onic stem cell-derived EBx cell lines to test, produce and market vaccine candidates |
The companies signed a licensing agree- ment in 2003 for the use of the cell line platforms for HIV and cancer recombinant vaccines; the new license is worldwide and nonexclusive; the agreement entails up-front payments, milestone payments and royalties (2/7) |
Vivalis* (France) |
Fort Dodge Animal Health (division of Wyeth) |
Vivalis granted Fort Dodge rights to the embryonic stem cell-derived EBx cell lines for evaluation |
Vivalis said its chicken and duck EBx cell lines could provide an alternative to embryonated eggs for the industrial viral vaccine production (3/1) |
Xencor Inc.* |
Boehringer-Ingelheim GmbH (Germany) |
Agreement to use Xencor's XmAb technology platform, including its Fc domains, to maximize the efficacy of BI's antibody drug candidates against selected targets |
Xencor will receive an up-front payment, and is eligible for license fees, milestones and royalties (2/14) |
XenoPort Inc. |
GlaxoSmithKline plc (UK) |
Co-development and commercialization agreement for XP13512 for restless legs syndrome and neuropathic pain |
The deal could total up to $640M in up-front and milestone payments (2/8) |
|
Notes: # The information in the chart does not cover agricultural agreements or those between biotech companies. * Private companies are indicated with an asterisk; ** Denotes the date the item ran in BioWorld International.Unless otherwise noted, stock symbols listed are on the Nasdaq market. AMEX = American Stock Exchange; CSE = Copenhagen Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSX = Toronto Stock Exchange. | |||
